1Cell.Ai profiles DNA, RNA, and protein from individual tumor cells to reveal patient subgroups, validate targets, and uncover resistance biology missed by tissue or bulk ctDNA.
Everything in the package, sent straight to your inbox. No spam.
NEW
NEW
FIRST
Most targeted therapies still select patients from a single marker, on a single slice of tissue, frozen at a single point in time. Tumors aren’t like that, and every month a program runs on averaged data, the answers stay hidden in cells no one profiled.
01
One stain, on one slice, with lab-to-lab variability, patients whose live tumor cells still express the target never make it into your trial. Real-time protein quantification on circulating tumor cells puts them back in.
Yes, with single-cell protein
02
Bulk ctDNA averages away the private, sub-clonal signals that flag resistance before it’s clinical. Resolve subclones and resistance biology that bulk measurements can obscure.
Yes, cell by cell
03
When response is heterogeneous, an arm-level “failure” can hide a responder subgroup. Single-cell target and resistance data lets you enrich enrollment, stratify smarter, and act before the readout, not after.
Yes, before the readout
Tissue, plasma ctDNA, and cell biopsy® each capture different biology. Cell biopsy® adds serial, blood-based access to intact tumor cells, with DNA, RNA, and protein read from the same single cell.
| Capability | Tissue | Plasma ctDNA | Cell Biopsy℠ |
|---|---|---|---|
| Serial blood-based sampling | No | Yes | Yes |
| Genomic profiling | Yes | Yes | Yes |
| Cellular RNA | Yes | No | Yes |
| Cellular protein | Yes | No | Yes |
| Intact tumor cells | Yes | No | Yes |
| Single-cell profiling | Possible | No | Yes |
| Direct assessment of cellular heterogeneity | Possible | Indirect | Yes |
Complementary analytes: cell biopsy℠ and plasma ctDNA are analyzed from the same 10 mL blood draw.
Our cell biopsy® platform captures live circulating tumor cells and reads DNA, RNA, and protein from the same cell: a true, cell-by-cell signature of heterogeneity and resistance.
DNA
Resolve driver status, even KRAS-mutant vs. wild- type, at single-cell resolution, catching subclones bulk assays miss.
RNA
Read what the tumor is actually doing: the difference between a mutation being present and a pathway being ON.
Protein
Quantify 20–30 ADC targets per cell with oligo- tagged antibodies: the real readout for ADC and bispecific selection.
From a simple blood draw to actionable therapy insights in six steps, one cell at a time.
01
02
03
04
05
06
Our cell biopsy® platform captures live circulating tumor cells and reads DNA, RNA, and protein from the same cell: a true, cell-by-cell signature of heterogeneity and resistance.
The multi-omic cell biopsy® platform: live CTC and ctDNA analysis, one cell at a time, for comprehensive molecular insight.
An AI-driven single-cell isolation and analysis system for high-resolution research in oncology and drug development.
Integrated AI analytics that unify complex multi- omic data across clinical trials and precision- oncology studies.
Results from 1Cell.Ai studies and validated cohorts, alongside independent clinical evidence, with every figure labeled by source.
of genomic alterations seen only in single-cell CTC-DNA, invisible to ctDNA alone (PDAC)
ADC targets quantified from a single cell: Trop-2, HER2, PSMA, Nectin-4, DLL3, FRα and more
omic layers, DNA + RNA + protein, from the same tumor cell
Cell biopsy® is active today across pharma, clinical, and academic programs, from target discovery through trial execution.
ADC biomarker development
Bispecific target validation
Clinical trial enrichment
Precision oncology programs
Translational research
Program details available under confidentiality. Talk to our team about yours.
Validate target expression, identify biomarker-defined subpopulations, and study resistance at single-cell resolution.
Non-invasive molecular insight to personalize therapy and track response between scans.
Single-cell DNA + RNA + protein and AI analytics tailored to your research question.
Exploring a partnership or a specific program? Talk to our team →
